Details of the Drug

General Information of Drug (ID: DM5JVAN)

Drug Name
Fingolimod
Synonyms 2-Amino-2-(4-octylphenethyl)propane-1,3-diol
Indication
Disease Entry ICD 11 Status REF
Primary progressive multiple sclerosis 8A40.1 Approved [1], [2]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 1 Molecular Weight (mw) 307.5
Topological Polar Surface Area (xlogp) 4.2
Rotatable Bond Count (rotbonds) 12
Hydrogen Bond Donor Count (hbonddonor) 3
Hydrogen Bond Acceptor Count (hbondacc) 3
ADMET Property
Clearance
The drug present in the plasma can be removed from the body at the rate of 1.53 mL/min/kg [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 144 hours [3]
Unbound Fraction
The unbound fraction of drug in plasma is 0.002% [3]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 17.3 L/kg [3]
Chemical Identifiers
Formula
C19H33NO2
IUPAC Name
2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol
Canonical SMILES
CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N
InChI
InChI=1S/C19H33NO2/c1-2-3-4-5-6-7-8-17-9-11-18(12-10-17)13-14-19(20,15-21)16-22/h9-12,21-22H,2-8,13-16,20H2,1H3
InChIKey
KKGQTZUTZRNORY-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
107970
ChEBI ID
CHEBI:63115
CAS Number
162359-55-9
DrugBank ID
DB08868
TTD ID
D07UHS
INTEDE ID
DR0696
ACDINA ID
D00276

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Sphingosine-1-phosphate receptor 1 (S1PR1) TT9JZCK S1PR1_HUMAN Modulator [2], [4]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 4F12 (CYP4F12) DED26GV CP4FC_HUMAN Substrate [5]
Cytochrome P450 4F2 (CYP4F2) DE3GT9C CP4F2_HUMAN Substrate [5]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Primary progressive multiple sclerosis
ICD Disease Classification 8A40.1
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Cytochrome P450 4F12 (CYP4F12) DME CYP4F12 4.68E-01 -5.96E-03 -2.58E-02
Cytochrome P450 4F2 (CYP4F2) DME CYP4F2 2.36E-01 -6.45E-02 -1.81E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Fingolimod
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Tecfidera DM2OVDT Major Additive immunosuppressive effects by the combination of Fingolimod and Tecfidera. Multiple sclerosis [8A40] [20]
Ocrelizumab DMEZ2KH Major Additive immunosuppressive effects by the combination of Fingolimod and Ocrelizumab. Multiple sclerosis [8A40] [20]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Fingolimod and Ozanimod. Multiple sclerosis [8A40] [20]
Coadministration of a Drug Treating the Disease Different from Fingolimod (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Fingolimod and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [21]
Ivosidenib DM8S6T7 Major Increased risk of ventricular arrhythmias by the combination of Fingolimod and Ivosidenib. Acute myeloid leukaemia [2A60] [22]
Arn-509 DMT81LZ Major Increased risk of ventricular arrhythmias by the combination of Fingolimod and Arn-509. Acute myeloid leukaemia [2A60] [22]
Oliceridine DM6MDCF Major Increased risk of ventricular arrhythmias by the combination of Fingolimod and Oliceridine. Acute pain [MG31] [22]
Siltuximab DMGEATB Major Additive immunosuppressive effects by the combination of Fingolimod and Siltuximab. Anemia [3A00-3A9Z] [20]
Ivabradine DM0L594 Moderate Increased risk of bradycardia by the combination of Fingolimod and Ivabradine. Angina pectoris [BA40] [20]
Bedaquiline DM3906J Major Increased risk of ventricular arrhythmias by the combination of Fingolimod and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [22]
Levalbuterol DM5YBO1 Moderate Increased risk of ventricular arrhythmias by the combination of Fingolimod and Levalbuterol. Asthma [CA23] [23]
Dupilumab DMOAD2Y Major Additive immunosuppressive effects by the combination of Fingolimod and Dupilumab. Atopic eczema [EA80] [20]
Eribulin DM1DX4Q Major Increased risk of ventricular arrhythmias by the combination of Fingolimod and Eribulin. Breast cancer [2C60-2C6Y] [20]
Talazoparib DM1KS78 Major Additive immunosuppressive effects by the combination of Fingolimod and Talazoparib. Breast cancer [2C60-2C6Y] [20]
LY2835219 DM93VBZ Major Additive immunosuppressive effects by the combination of Fingolimod and LY2835219. Breast cancer [2C60-2C6Y] [20]
Palbociclib DMD7L94 Major Additive immunosuppressive effects by the combination of Fingolimod and Palbociclib. Breast cancer [2C60-2C6Y] [20]
PF-04449913 DMSB068 Major Additive immunosuppressive effects by the combination of Fingolimod and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [20]
Olodaterol DM62B78 Moderate Increased risk of ventricular arrhythmias by the combination of Fingolimod and Olodaterol. Chronic obstructive pulmonary disease [CA22] [24]
Vilanterol DMF5EK1 Moderate Increased risk of prolong QT interval by the combination of Fingolimod and Vilanterol. Chronic obstructive pulmonary disease [CA22] [23]
Aflibercept DMT3D5I Major Additive immunosuppressive effects by the combination of Fingolimod and Aflibercept. Colorectal cancer [2B91] [20]
Osilodrostat DMIJC9X Major Increased risk of ventricular arrhythmias by the combination of Fingolimod and Osilodrostat. Cushing syndrome [5A70] [22]
Polatuzumab vedotin DMF6Y0L Major Additive immunosuppressive effects by the combination of Fingolimod and Polatuzumab vedotin. Diffuse large B-cell lymphoma [2A81] [20]
Lisocabtagene maraleucel DMP45ME Major Additive immunosuppressive effects by the combination of Fingolimod and Lisocabtagene maraleucel. Diffuse large B-cell lymphoma [2A81] [20]
Axicabtagene ciloleucel DMYHN59 Major Additive immunosuppressive effects by the combination of Fingolimod and Axicabtagene ciloleucel. Diffuse large B-cell lymphoma [2A81] [20]
Deutetrabenazine DMUPFLI Major Increased risk of ventricular arrhythmias by the combination of Fingolimod and Deutetrabenazine. Dystonic disorder [8A02] [22]
Ingrezza DMVPLNC Major Increased risk of ventricular arrhythmias by the combination of Fingolimod and Ingrezza. Dystonic disorder [8A02] [22]
Cannabidiol DM0659E Moderate Increased risk of hepatotoxicity by the combination of Fingolimod and Cannabidiol. Epileptic encephalopathy [8A62] [25]
Bay 80-6946 DMLOS5R Major Additive immunosuppressive effects by the combination of Fingolimod and Bay 80-6946. Follicular lymphoma [2A80] [20]
Avapritinib DMK2GZX Major Additive immunosuppressive effects by the combination of Fingolimod and Avapritinib. Gastrointestinal stromal tumour [2B5B] [20]
Levobetaxolol DMSREPX Moderate Increased risk of atrioventricular block by the combination of Fingolimod and Levobetaxolol. Glaucoma [9C61] [20]
177Lu-DOTATATE DMT8GVU Major Additive immunosuppressive effects by the combination of Fingolimod and 177Lu-DOTATATE. Hepatitis virus infection [1E50-1E51] [20]
Brentuximab vedotin DMWLC57 Major Additive immunosuppressive effects by the combination of Fingolimod and Brentuximab vedotin. Hodgkin lymphoma [2B30] [20]
Fostemsavir DM50ILT Major Increased risk of ventricular arrhythmias by the combination of Fingolimod and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [22]
Teriflunomide DMQ2FKJ Major Additive immunosuppressive effects by the combination of Fingolimod and Teriflunomide. Hyper-lipoproteinaemia [5C80] [26]
Levamlodipine DM92S6N Moderate Increased risk of atrioventricular block by the combination of Fingolimod and Levamlodipine. Hypertension [BA00-BA04] [20]
Brigatinib DM7W94S Major Additive immunosuppressive effects by the combination of Fingolimod and Brigatinib. Lung cancer [2C25] [20]
Ceritinib DMB920Z Major Increased risk of ventricular arrhythmias by the combination of Fingolimod and Ceritinib. Lung cancer [2C25] [22]
Lurbinectedin DMEFRTZ Major Additive immunosuppressive effects by the combination of Fingolimod and Lurbinectedin. Lung cancer [2C25] [20]
Alectinib DMP1I6Y Moderate Increased risk of atrioventricular block by the combination of Fingolimod and Alectinib. Lung cancer [2C25] [20]
Osimertinib DMRJLAT Major Additive immunosuppressive effects by the combination of Fingolimod and Osimertinib. Lung cancer [2C25] [20]
Selpercatinib DMZR15V Major Increased risk of ventricular arrhythmias by the combination of Fingolimod and Selpercatinib. Lung cancer [2C25] [22]
Belimumab DM3OBQF Major Additive immunosuppressive effects by the combination of Fingolimod and Belimumab. Lupus erythematosus [4A40] [20]
Obinutuzumab DM3BVAE Major Additive immunosuppressive effects by the combination of Fingolimod and Obinutuzumab. Mature B-cell leukaemia [2A82] [20]
Idelalisib DM602WT Major Additive immunosuppressive effects by the combination of Fingolimod and Idelalisib. Mature B-cell leukaemia [2A82] [20]
GDC-0199 DMH0QKA Major Additive immunosuppressive effects by the combination of Fingolimod and GDC-0199. Mature B-cell leukaemia [2A82] [20]
IPI-145 DMWA24P Major Additive immunosuppressive effects by the combination of Fingolimod and IPI-145. Mature B-cell leukaemia [2A82] [20]
Acalabrutinib DM7GCVW Major Additive immunosuppressive effects by the combination of Fingolimod and Acalabrutinib. Mature B-cell lymphoma [2A85] [20]
Blinatumomab DMGECIJ Major Additive immunosuppressive effects by the combination of Fingolimod and Blinatumomab. Mature B-cell lymphoma [2A85] [20]
Ibrutinib DMHZCPO Major Additive immunosuppressive effects by the combination of Fingolimod and Ibrutinib. Mature B-cell lymphoma [2A85] [20]
Tisagenlecleucel DMM9BJD Major Additive immunosuppressive effects by the combination of Fingolimod and Tisagenlecleucel. Mature B-cell lymphoma [2A85] [20]
Ponatinib DMYGJQO Major Additive immunosuppressive effects by the combination of Fingolimod and Ponatinib. Mature B-cell lymphoma [2A85] [20]
Vemurafenib DM62UG5 Major Increased risk of ventricular arrhythmias by the combination of Fingolimod and Vemurafenib. Melanoma [2C30] [22]
LGX818 DMNQXV8 Major Increased risk of ventricular arrhythmias by the combination of Fingolimod and LGX818. Melanoma [2C30] [22]
Carfilzomib DM48K0X Major Additive immunosuppressive effects by the combination of Fingolimod and Carfilzomib. Multiple myeloma [2A83] [20]
Selinexor DMBD4K3 Major Additive immunosuppressive effects by the combination of Fingolimod and Selinexor. Multiple myeloma [2A83] [20]
Belantamab mafodotin DMBT3AI Major Additive immunosuppressive effects by the combination of Fingolimod and Belantamab mafodotin. Multiple myeloma [2A83] [20]
Daratumumab DMKCIUZ Major Additive immunosuppressive effects by the combination of Fingolimod and Daratumumab. Multiple myeloma [2A83] [20]
Deflazacort DMV0RNS Major Additive immunosuppressive effects by the combination of Fingolimod and Deflazacort. Muscular dystrophy [8C70] [20]
Ruxolitinib DM7Q98D Major Additive immunosuppressive effects by the combination of Fingolimod and Ruxolitinib. Myeloproliferative neoplasm [2A20] [20]
Inebilizumab DMI0RHA Major Additive immunosuppressive effects by the combination of Fingolimod and Inebilizumab. Nervous system paraneoplastic/autoimmune disorder [8E4A] [20]
Atezolizumab DMMF8U0 Major Additive immunosuppressive effects by the combination of Fingolimod and Atezolizumab. Non-small cell lung cancer [2C25] [20]
Entrectinib DMMPTLH Major Additive immunosuppressive effects by the combination of Fingolimod and Entrectinib. Non-small cell lung cancer [2C25] [20]
Olaparib DM8QB1D Major Additive immunosuppressive effects by the combination of Fingolimod and Olaparib. Ovarian cancer [2C73] [20]
Rucaparib DM9PVX8 Major Additive immunosuppressive effects by the combination of Fingolimod and Rucaparib. Ovarian cancer [2C73] [20]
MK-4827 DMLYGH4 Major Additive immunosuppressive effects by the combination of Fingolimod and MK-4827. Ovarian cancer [2C73] [20]
Triclabendazole DMPWGBR Major Increased risk of ventricular arrhythmias by the combination of Fingolimod and Triclabendazole. Parasitic worm infestation [1F90] [22]
Macimorelin DMQYJIR Major Increased risk of ventricular arrhythmias by the combination of Fingolimod and Macimorelin. Pituitary gland disorder [5A60-5A61] [22]
Lefamulin DME6G97 Major Increased risk of ventricular arrhythmias by the combination of Fingolimod and Lefamulin. Pneumonia [CA40] [22]
Enzalutamide DMGL19D Major Increased risk of ventricular arrhythmias by the combination of Fingolimod and Enzalutamide. Prostate cancer [2C82] [22]
Relugolix DMK7IWL Major Increased risk of ventricular arrhythmias by the combination of Fingolimod and Relugolix. Prostate cancer [2C82] [22]
Brodalumab DMASDQ6 Major Additive immunosuppressive effects by the combination of Fingolimod and Brodalumab. Psoriasis [EA90] [20]
Tildrakizumab DMLW9HG Major Additive immunosuppressive effects by the combination of Fingolimod and Tildrakizumab. Psoriasis [EA90] [20]
Risankizumab DMM32GT Major Additive immunosuppressive effects by the combination of Fingolimod and Risankizumab. Psoriasis [EA90] [20]
Ixekizumab DMXW92T Major Additive immunosuppressive effects by the combination of Fingolimod and Ixekizumab. Psoriasis [EA90] [20]
Upadacitinib DM32B5U Major Additive immunosuppressive effects by the combination of Fingolimod and Upadacitinib. Rheumatoid arthritis [FA20] [20]
Baricitinib DM4ONW5 Major Additive immunosuppressive effects by the combination of Fingolimod and Baricitinib. Rheumatoid arthritis [FA20] [20]
Tofacitinib DMBS370 Major Additive immunosuppressive effects by the combination of Fingolimod and Tofacitinib. Rheumatoid arthritis [FA20] [20]
Sarilumab DMOGNXY Major Additive immunosuppressive effects by the combination of Fingolimod and Sarilumab. Rheumatoid arthritis [FA20] [20]
Mogamulizumab DMISH0Z Major Additive immunosuppressive effects by the combination of Fingolimod and Mogamulizumab. Sezary syndrome [2B02] [20]
LEE011 DMMX75K Major Increased risk of ventricular arrhythmias by the combination of Fingolimod and LEE011. Solid tumour/cancer [2A00-2F9Z] [20]
Pitolisant DM8RFNJ Major Increased risk of ventricular arrhythmias by the combination of Fingolimod and Pitolisant. Somnolence [MG42] [22]
Pomalidomide DMTGBAX Major Additive immunosuppressive effects by the combination of Fingolimod and Pomalidomide. Systemic sclerosis [4A42] [20]
Lenvatinib DMB1IU4 Major Increased risk of ventricular arrhythmias by the combination of Fingolimod and Lenvatinib. Thyroid cancer [2D10] [22]
Cabozantinib DMIYDT4 Major Increased risk of ventricular arrhythmias by the combination of Fingolimod and Cabozantinib. Thyroid cancer [2D10] [22]
Durvalumab DM4PVDY Major Additive immunosuppressive effects by the combination of Fingolimod and Durvalumab. Ureteral cancer [2C92] [20]
⏷ Show the Full List of 82 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Mannitol E00103 6251 Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Magnesium stearate E00208 11177 lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Fingolimod 0.5 mg capsule 0.5 mg Oral Capsule Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2407).
2 Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
3 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4 Emerging oral drugs for multiple sclerosis. Expert Opin Emerg Drugs. 2008 Sep;13(3):465-77.
5 CYP4F enzymes are responsible for the elimination of fingolimod (FTY720), a novel treatment of relapsing multiple sclerosis. Drug Metab Dispos. 2011 Feb;39(2):191-8.
6 Cloning and characterization of CYP4F21: a prostaglandin E2 20-hydroxylase of ram seminal vesicles. Arch Biochem Biophys. 2001 May 1;389(1):123-9.
7 cDNA cloning and expression of a novel cytochrome p450 (cyp4f12) from human small intestine. Biochem Biophys Res Commun. 2001 Feb 2;280(4):1135-41.
8 Human enteric microsomal CYP4F enzymes O-demethylate the antiparasitic prodrug pafuramidine. Drug Metab Dispos. 2007 Nov;35(11):2067-75.
9 Discovery, characterization, and significance of the cytochrome P450 omega-hydroxylase pathway of vitamin E catabolism. Ann N Y Acad Sci. 2004 Dec;1031:13-21.
10 Product information - Gilenya.
11 Role of cytochrome P450 enzymes in the bioactivation of polyunsaturated fatty acids. Biochim Biophys Acta. 2011 Jan;1814(1):210-22.
12 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
13 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
14 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
15 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
16 Sphingosine 1-Phosphate Receptor Modulators in Multiple Sclerosis. CNS Drugs. 2015 Jul;29(7):565-75.
17 Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond. Nat Rev Drug Discov. 2013 Sep;12(9):688-702.
18 Exploration of amino alcohol derivatives as novel, potent, and highly selective sphingosine-1-phosphate receptor subtype-1 agonists. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2520-4.
19 ASP4058, a novel agonist for sphingosine 1-phosphate receptors 1 and 5, ameliorates rodent experimental autoimmune encephalomyelitis with a favorable safety profile. PLoS One. 2014 Oct 27;9(10):e110819.
20 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
21 Cerner Multum, Inc. "Australian Product Information.".
22 Canadian Pharmacists Association.
23 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
24 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
25 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
26 Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.